Close

We use cookies to improve your experience of our website. Privacy Policy

Skip to main content
Menu

Dr Barrie Peck

Barrie Peck

ECR/Lecturer

Barts Cancer Institute, Department of Tumour Biology
School of Medicine & Dentistry, Queen Mary University of London
+44 (0)20 7882 3558

www.bartscancer.london/staff/dr-barrie-peck/

ORCiD Google Scholar

Research

Interests

We utilise multicellular spheroid models to recapitulate the unfavourable tumour microenvironment (TME) encountered in vivo. We are particularly interested in nutrient stress and cancer cell metabolism that take place with the TME.

Publications of specific relevance to Predictive in vitro Models

Publications

2020

Kapara A, Vannini A and Peck B (2020). A micronutrient with major effects on cancer cell viability. Nature Research  Nature Metabolism  10.1038/s42255-020-0244-3

2019

Peck B and Schulze A (2019). Lipid Metabolism at the Nexus of Diet and Tumor Microenvironment. Trends in Cancer  vol. 5, (11) 693-703. 10.1016/j.trecan.2019.09.007
Jones DT, Valli A, Haider S, Zhang Q, Smethurst EA, Schug ZT, Peck B, Aboagye EO, Critchlow SE, Schulze A, Gottlieb E, Wakelam MJO and Harris AL (2019). 3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers. American Association For Cancer Research  Molecular Cancer Therapeutics  vol. 18, (2) 376-388. 10.1158/1535-7163.MCT-17-0857

2018

Miess H, Dankworth B, Gouw AM, Rosenfeldt M, Schmitz W, Jiang M, Saunders B, Howell M, Downward J, Felsher DW, Peck B and Schulze A (2018). The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. Oncogene  vol. 37, (40) 5435-5450. 10.1038/s41388-018-0315-z

2017

Leonidou A, Peck B and Natrajan R (2017). Identification and Validation of Driver Kinases from Next-Generation Sequencing Data. Methods Mol Biol  vol. 1636, 179-195. 10.1007/978-1-4939-7154-1_12

2016

Morrison E, Wai P, Leonidou A, Bland P, Khalique S, Farnie G, Daley F, Peck B and Natrajan R (2016). Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures. J Vis Exp  (118) 10.3791/54738
Maguire SL, Peck B, Wai PT, Campbell J, Barker H, Gulati A, Daley F, Vyse S, Huang P, Lord CJ, Farnie G, Brennan K and Natrajan R (2016). Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. J Pathol  vol. 240, (3) 315-328. 10.1002/path.4778
Peck B and Schulze A (2016). Lipid desaturation - the next step in targeting lipogenesis in cancer? Febs J  vol. 283, (15) 2767-2778. 10.1111/febs.13681
Peck B, Schug ZT, Zhang Q, Dankworth B, Jones DT, Smethurst E, Patel R, Mason S, Jiang M, Saunders R, Howell M, Mitter R, Spencer-Dene B, Stamp G, McGarry L, James D, Shanks E, Aboagye EO, Critchlow SE, Leung HY, Harris AL, Wakelam MJO, Gottlieb E and Schulze A (2016). Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer Metab  vol. 4, 10.1186/s40170-016-0146-8

2015

Lewis CA, Brault C, Peck B, Bensaad K, Griffiths B, Mitter R, Chakravarty P, East P, Dankworth B, Alibhai D, Harris AL and Schulze A (2015). SREBP maintains lipid biosynthesis and viability of cancer cells under lipid- and oxygen-deprived conditions and defines a gene signature associated with poor survival in glioblastoma multiforme. Oncogene  vol. 34, (40) 5128-5140. 10.1038/onc.2014.439
Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, Goodwin LM, Smethurst E, Mason S, Blyth K, McGarry L, James D, Shanks E, Kalna G, Saunders RE, Jiang M, Howell M, Lassailly F, Thin MZ, Spencer-Dene B, Stamp G, van den Broek NJF, Mackay G, Bulusu V, Kamphorst JJ, Tardito S, Strachan D, Harris AL, Aboagye EO and Critchlow SE (2015). Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell  vol. 27, (1) 57-71. 10.1016/j.ccell.2014.12.002

2014

Bensaad K, Favaro E, Lewis CA, Peck B, Lord S, Collins JM, Pinnick KE, Wigfield S, Buffa FM, Li J-L, Zhang Q, Wakelam MJO, Karpe F, Schulze A and Harris AL (2014). Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep  vol. 9, (1) 349-365. 10.1016/j.celrep.2014.08.056
Peck B and Schulze A (2014). Cholesteryl esters: fueling the fury of prostate cancer. Cell Metab  vol. 19, (3) 350-352. 10.1016/j.cmet.2014.02.012
Schug Z, Peck B, Jones D, Zhang Q, Alam I, Witney T, Smethurst E, Grosskurth S, Harris A, Critchlow S, Aboagye E, Wakelam M, Schulze A and Gottlieb E (2014). Acetyl-coA synthetase 2 promotes acetate utilization and maintains cell growth under metabolic stress. Cancer & Metabolism  vol. 2, (Suppl 1) O9-O9. 10.1186/2049-3002-2-S1-O9

2013

Baenke F, Peck B, Miess H and Schulze A (2013). Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech  vol. 6, (6) 1353-1363. 10.1242/dmm.011338
Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, Ferber EC, Konisti S, Peck B, Miess H, East P, Wakelam M, Harris AL and Schulze A (2013). Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab  vol. 1, (1) 10.1186/2049-3002-1-3
Peck B, Ferber EC and Schulze A (2013). Antagonism between FOXO and MYC Regulates Cellular Powerhouse. Front Oncol  vol. 3, 10.3389/fonc.2013.00096

2012

Ferber EC, Peck B, Delpuech O, Bell GP, East P and Schulze A (2012). FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Cell Death Differ  vol. 19, (6) 968-979. 10.1038/cdd.2011.179

2011

Peck B and Schulze A (2011). A role for the cancer-associated miR-106b~25 cluster in neuronal stem cells. Aging (Albany Ny)  vol. 3, (4) 329-331. 10.18632/aging.100302

2010

Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Charles Coombes R, Fuchter MJ, Hsiao CD and Lam EWF (2010). SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Molecular Cancer Therapeutics  vol. 9, (4) 844-855. 10.1158/1535-7163.MCT-09-0971
Kwok JM-M, Peck B, Monteiro LJ, Schwenen HDC, Millour J, Coombes RC, Myatt SS and Lam EW-F (2010). FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res  vol. 8, (1) 24-34. 10.1158/1541-7786.MCR-09-0432

2009

Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, Wang J, Guest SK, Filipovic A, Gojis O, Palmieri C, Peston D, Shousha S, Yu Q, Sicinski P, Coombes RC and Lam EW-F (2009). FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol  vol. 35, (1) 57-68. 10.3892/ijo_00000313
McGovern UB, Francis RE, Peck B, Guest SK, Wang J, Myatt SS, Krol J, Kwok JM-M, Polychronis A, Coombes RC and Lam EW-F (2009). Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther  vol. 8, (3) 582-591. 10.1158/1535-7163.MCT-08-0805